Ticker

No recent analyst price targets found for ZCMD.

Latest News for ZCMD

Zhongchao Inc. (NASDAQ:ZCMD) Sees Large Decline in Short Interest

Zhongchao Inc. (NASDAQ: ZCMD - Get Free Report) saw a significant drop in short interest in March. As of March 13th, there was short interest totaling 32,299 shares, a drop of 77.6% from the February 26th total of 143,892 shares. Based on an average daily volume of 26,653 shares, the days-to-cover ratio is presently 1.2 days.

Defense World • Mar 27, 2026
Zhongchao (NASDAQ:ZCMD) & Precipio (NASDAQ:PRPO) Financial Review

Precipio (NASDAQ: PRPO - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of recent ratings

Defense World • Mar 8, 2026
Zhongchao Inc. Announces 1-for-8 Share Consolidation

SHANGHAI, Feb. 26, 2026 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that the Company will effectuate a 1-for-8 share consolidation of the Company's ordinary shares of US$0.001 par value each (the "Share Consolidation"). Beginning with the opening of…

PRNewsWire • Feb 26, 2026
Zhongchao Inc. (NASDAQ:ZCMD) Short Interest Up 610.1% in February

Zhongchao Inc. (NASDAQ: ZCMD - Get Free Report) saw a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 155,000 shares, an increase of 610.1% from the January 29th total of 21,827 shares. Based on an average daily volume of 8,954,725 shares, the days-to-cover ratio is

Defense World • Feb 26, 2026
Financial Comparison: 10x Genomics (NASDAQ:TXG) vs. Zhongchao (NASDAQ:ZCMD)

10x Genomics (NASDAQ: TXG - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Analyst Ratings This is a summary of current ratings

Defense World • Feb 12, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ZCMD.

No House trades found for ZCMD.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top